Nantes, France – July 13, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings to the Company the experience of remarkable successes within the pharmaceutical industry, through a range of international responsibilities and in different therapeutic areas, including oncology.
Dominique Costantini, President of OSE Immunotherapeutics, declares: “The Board of Directors is very pleased to announce the appointment of Alexis Vandier as the new Chief Executive Officer of OSE Immunotherapeutics. With his strong international managerial experience and his clear understanding of OSE’s strengths and potential, we are convinced that Alexis is highly qualified to lead the acceleration of the Company’s growth and lead it to the next stage. of its development. His strategic and inspiring leadership, combined with his very good knowledge of the pharmaceutical industry, will make it possible to provide innovative and effective therapeutic solutions to patients and high value to players in our field”.